| ASSET | QUARTER | % RETURN |
|---|---|---|
Quantum Computing (QUBT) | Q1 2018 | 1,400% |
Acm Research (ACMR) | Q1 2018 | 134.29% |
Arrowhead Pharmaceuticals (ARWR) | Q1 2018 | 95.39% |
Enphase Energy (ENPH) | Q1 2018 | 91.21% |
Crispr Therapeutics (CRSP) | Q1 2018 | 90.46% |
Spyre Therapeutics (SYRE) | Q1 2018 | 82.35% |
Virtu Financial (VIRT) | Q1 2018 | 81.81% |
Xenon Pharmaceuticals (XENE) | Q1 2018 | 75% |
Skyline (SKY) | Q1 2018 | 72.28% |
TG Therapeutics (TGTX) | Q1 2018 | 71.08% |
PTC Therapeutics (PTCT) | Q1 2018 | 60.5% |
CleanSpark (CLSK) | Q1 2018 | 57% |
Zymeworks Inc Common Stock (ZYME) | Q1 2018 | 56.31% |
Perpetua Resources (PPTA) | Q1 2018 | 53.05% |
Sunrun (RUN) | Q1 2018 | 51.87% |
Ocular Therapeutix (OCUL) | Q1 2018 | 44.99% |
Enova International (ENVA) | Q1 2018 | 43.65% |
ADMA Biologics (ADMA) | Q1 2018 | 42.86% |
RadNet (RDNT) | Q1 2018 | 42.57% |
Surgery Partners (SGRY) | Q1 2018 | 41.74% |
Match (MTCH) | Q1 2018 | 41.08% |
Vipshop (VIPS) | Q1 2018 | 40.85% |
Wix (WIX) | Q1 2018 | 39.44% |
Addus HomeCare (ADUS) | Q1 2018 | 39.4% |
Abercrombie & Fitch (ANF) | Q1 2018 | 38.4% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
